Introduction
In oncology, quality of life (QL) has become an essential criterion for evaluating the effects of therapy in clinical trials. So far, in adult patients suffering from acute leukemia assessment of QL has not been considered possible due to poor prognosis, the acute course and the severity of the disease and/or treatment-associated symptoms. 1 Advances in chemotherapy significantly prolong survival of patients with acute myeloid leukemia (AML) and may even cure a significant percentage (25-30%) of patients. 2 There is evidence that intensification and prolonged maintenance treatment increase treatment response and curative rates as well as long-term prognosis. 3 As intensive therapy might be associated with high morbidity, the benefits offered by intensive treatment should be weighted against potential impairment in QL. Therefore, the assessment of QL of patients undergoing chemotherapy is of growing interest. The study presented here was designed to evaluate QL in patients with AML treated according to the protocol of the German AML-Cooperative Group based in Mü nster, Germany. Survival and QL being the most relevant patient outcome measurements, 4 the aim of this study was to monitor QL and subjective well-being of those patients actually responding to intensive treatment.
According to current standards [5] [6] [7] at least three domains should be included in order to evaluate QL: physical, psycho-logical and functional status. Patients' perception of their subjective QL is a dynamic concept and can change as an adaptational process interacting with life circumstances. The assessment of QL is usually achieved by an evaluation of specific components contributing to the QL construct.
Materials and methods

Measurements of quality of life
An individual's health-related QL is not observable in a direct way, but can only be concluded from different components. Therefore, an instrument to measure QL should be multidimensional and should comprise the relevant categories of variables: physical complaints, psychological distress, social interaction and functional status. The instrument should be patient-based and designed for self-assessment, as the patient is the best and sometimes the only source of information about the impact of disease and treatment on his/her wellbeing.
Based on conceptual, methodological and practical criteria, we used the QL-questionnaire developed by the European Organization for Research and Treatment of Cancer: EORTC QLQ-C 30. 8 The EORTC QLQ-C 30 is a 30-item self-report questionnaire composed of multi-item scales and single items that reflect the multidimensionality of the QL construct. Several functional scales evaluate physical, emotional, social and cognitive functioning as well as role functioning and global quality of life. Three symptom scales assess fatigue, pain and nausea/emesis. Six single items measure financial impact and physical symptoms such as dyspnea, sleep disturbance, appetite, diarrhea and constipation. The time-frame is the past week.
The questionnaire is a well-validated instrument that demonstrates high reliability and validity in different groups of cancer patients 9 and is sensitive to change in patients' health status over time. 8 The items constructing the different subscales are applicable for our subjects during inpatient treatment. Throughout treatment, patients are not isolated in single rooms, they share double rooms. Patients perform necessary activities like dressing, showering, taking care of their personal hygiene, getting up for meals, and -as long as they are not in aplasia -patients can move around the hospital and the surrounding parks and make use of the hospital's various facilities such as cafeteria, shops, hairdresser and concerts.
In addition to the core questionnaire QLQ C-30, a novel leukemia-specific module was developed by our study group, according to EORTC criteria. The module was constructed mainly to assess diagnosis-specific and treatment-related symptoms. For the first time, this module was being used in a longitudinal study. These results will be published at a later time. To verify clinical validity, ratings on the Eastern Cooperative Oncology Group (ECOG) performance status scale 10 at the beginning of treatment were added as clinical variables.
Treatment regimens
Patients were treated according to the protocol of the German AML-Cooperative Group. 11 Chemotherapy is age-adapted double-induction including high-dose Ara-C, consolidation and prolonged maintenance for 3 years.
Patients under age 60 uniformly receive a standard twocourse induction including 9-day TAD (a combination of thioguanin, cytosine-arabinoside and daunorubicin) and 5-day HAM (high-dose Ara-C plus mitoxantrone) with the second course starting on day 21, regardless of the reponse to the first course. Patients above age 60 receive the second treatment course only if response has been poor and CR criteria could not be achieved.
Post-remission treatment is TAD 9 consolidation and monthly myelosuppressive chemotherapy, applying 5-day courses of Ara-C rotatingly combined with thioguanin or daunorubicin or cyclophosphamide.
Design of the study QL will be analyzed during induction therapy, consolidation and maintenance therapy over 3 years, evaluating defined specific parameters at 12 different time-points. The questionnaires are administered in the first four courses of chemotherapy (double induction, consolidation, first and second cycle of maintenance therapy) during inpatient treatment, before and after drug-induced myelo-aplasia. Every 6 months during outpatient treatment patients assess a set of mailed questionnaires up to the end of their treatment. Patients' individual perception of their disease and therapy is evaluated by a semi-structured interview during the first cycle of maintenance therapy ( Figure 1 ).
The doctors who treated the patients were not aware of the ongoing results of the study. The patients taking part in our QL study knew that the doctors were not aware of the ongoing results in individual patients.
The design of the study was approved by the Ethical Committee of the School of Medicine, University of Mü nster.
Figure 1
Design of the study for the inpatient treatment phase: time points of measurements according to the phase of treatment.
Patients
The study was conducted at the Department of Internal Medicine (Haematology/Oncology) at the University of Mü nster, Germany. All patients, aged 16 to 70, admitted with newly diagnosed acute myeloid leukemia were approached to participate in the study. Of a total of 66 potential patients, 61 agreed to participate and were encompassed in the study. As the aim of the study is to assess subjective QL in patients responding to prolonged intensive treatment, the analysis presented here is based on a defined subset of patients who have completed the whole inpatient treatment regimen and were thus responding to this kind of treatment. Restricting the sample to those patients with CR and disease-free survival throughout inpatient treatment reduces the number of patients available for analysis. This strategy has been chosen according to Hopwood et al. 12 In order to assess the impact of this specific kind of prolonged and intensive therapy on patients' subjective well-being over time, it is necessary to consider a subset of patients with full data sets and a sufficiently long followup period.
Here we will report changes in QL during inpatient treatment (T1-T8) for those patients being recruited between March 1992 and September 1995. The study is still continuing and the final results will be reported at a later time. Changes in QL during outpatient treatment and an analysis of the overall sample to evaluate QL of patients who failed to complete the treatment successfully will be included in the final report.
Data collection
Great care was given to data collection. Data collection required a high organizational level which made it necessary to have a group of at least five people working on the team. Patients being recruited for the QL study were being closely monitored in regard to their course of treatment. So whenever a patient was admitted for the next course of treatment, he was seen by a member of our team who supplied the patient with the appropriate questionnaire. A few days later, the ques-tionnaire was picked up again, usually by the same person or another member of our team. The same procedure was followed when patients reached the end of the myelo-aplastic phase.
Statistical analyses
Changes in patients' assessments of the various EORTC subscales were evaluated by doing multivariate analyses of variance for repeated measurements (SPSS Win 6.0.1) which is the appropriate procedure recommended by the EORTC. Transcriptions of the interviews were categorised by two independent raters, and a content analysis was done by counting the frequencies of statements in each category. Inter-rater reliability was calculated by Pearson's r = 0.89.
Results
Twenty-eight out of 61 enrolled patients were able to complete all the courses of inpatient treatment. Nineteen of all patients relapsed or died at various time-points before completion of inpatient treatment. According to AMLCG criteria, 11 nine patients were excluded from the treatment protocol because of therapy associated complications (eg cardiac failure Ͼ NYHA II), three patients underwent a bone marrow transplantation after complete remission. Two patients ceased to take part in the study due to personal problems unrelated to their disease or therapy.
Sociodemographic variables of the population studied are shown in Table 1 . There was no statistical significant difference in age or sex between those 28 patients who were able to complete inpatient treatment and those 31 who were not able to do so.
Furthermore, we tested for statistical significant effects of sociodemographic variables on patients' self-assessed QL (one-way analyses of variance). Patients' answers did not vary significantly by the parameters age, sex, socioeconomic class, marital status and educational status.
Pretreatment scores on the QLQ-C 30 were cross-checked against ratings on the ECOG performance status scale to verify clinical validity. 10 As expected, a close relationship between performance status and the QLQ-C 30 subscales 'Physical Functioning', 'Role Functioning' and 'Subjective QL' could be established (Figure 2) .
Those patients having completed the course of inpatient treatment are evaluated for changes in the conceptually distinct QL domains. Patients being excluded from the study (n = 33); patients having completed the course of inpatient treatment (n = 28)
Figure 2
Group differences between high and low ratings on ECOG-Performance Scale and EORTC-QLQ C30 subscales 'Physical Functioning', 'Role Functioning', 'Global Health Status' (high performance status: ECOG score 3-4, low performance status: ECOG score 0-2).
EORTC QLQ-C 30 Functional Scales
Physical Functioning (P Ͻ 0.001, F = 8.88, df = 7), Role Functioning (P = 0.001, F = 3.60, df = 7), Social Functioning (P = 0.007, F = 2.91, df = 7) and Emotional Functioning (P Ͻ 0.001, F = 5.16, df = 7) significantly improve from beginning of chemotherapy to the end of inpatient treatment. Individual assessment of Global Health Status and Subjective QL (P Ͻ 0.001, F = 13.56, df = 7) significantly improves over the same time (Figure 3) . However, Cognitive Functioning was not uniformly influenced by therapy (P Ͼ 0.1).
EORTC QLQ-C 30 Symptom Scales
Various symptoms, mostly side-effects of therapy, vary during the course of treatment (Figure 4) . Accordingly, patients suffer significantly less from fatigue (P Ͻ 0.001, F = 9.27, df = 7), nausea/emesis (P Ͻ 0.001, F = 5.96, df = 7), loss of appetite (P Ͻ 0.001, F = 9.52, df = 7) and diarrhea (P Ͻ 0.001, F = 3.594, df = 7) at the end of inpatient treatment. In addition, patients complain less about pain (P = 0.001, F = 3.56, df = 7), dyspnea (P Ͻ 0.001, F = 4.93, df = 7) and sleep disturbance (P = 0.001, F = 3.85, df = 7).
Interviews
The interviews in our study underline these results and highlight the different aspects of patients' QL. Twenty-three patients were able to be interviewed during the first cycle of maintenance therapy. The content analysis of the data shows to what extent patients rely on the emotional support they get not only from their family but from nurses and medical staff as well. Twelve out of 23 patients considered this support as a very important factor contributing to their QL during inpatient treatment. Other aspects of the inpatient setting diminish patients' QL. Four patients complained about the lack of privacy, three patients were bothered by boredom and the lack of entertainment facilities when staying in hospital for such a long time. Seven out of 23 patients regarded the insufficient quality of hospital food as one of the most important aspects of QL.
The analysis of the interviews reveals certain major factors influencing patients' psychosocial well-being. Undergoing treatment for such a long time makes it difficult for patients to cope with their disease. Seventeen out of 23 patients interviewed find it hard to set up a daily routine at home as they have to go back frequently to hospital for several courses of inpatient therapy. During outpatient treatment the monthly course of therapy means an interruption of their everyday routine like work, family, household tasks. 'Leading a plain, ordinary life, back in my daily routine' is a highly desired aim for most patients. Uncertainty about long-term remission is another threat to patients' psychosocial well-being. In the interview, seven out of 23 patients could talk openly about their fear of a relapse.
Discussion
The German AML-Cooperative Group 2,3 has shown that a multiple-step chemotherapy combining double-induction, intensified consolidation and long-term maintenance can improve both treatment response and long-term prognosis.
The aim of the study was to evaluate QL in patients undergoing treatment as an important parameter. In order to assess the impact of prolonged and intensive AML therapy on patients' subjective QL, only patients with CR and disease-free survival throughout inpatient treatment were included in the analysis. Due to the severity of the disease and the treatment-associated symptoms, uncertainty about their individual prognosis is common to all patients undergoing treatment. So it is not to be expected that patients who fail to complete treatment successfully, might experience a different kind of QL from the very beginning of therapy. In a one-way analysis of variance, we compared patients who completed inpatient treatment with those patients who were excluded from the study at various time-points, due to treatment complications or relapse/death or withdrawal. The factor 'duration of participation' could not account for any variance in patients' selfassessed QL. So patients being excluded from the study do not show significant differences in their evaluation of their subjective QL during treatment compared to the 28 patients in our analysis.
As far as the results of the AMLCG studies 2, 3 show, treatment response during inpatient treatment is not worse in older patients whereas long-term prognosis definitely is. During the outpatient treatment phase, older patients seem to have more therapy-associated complications/relapses compared to younger patients. The assessment of QL and subjective wellbeing is an individual process which is influenced by various cognitive and emotional factors. QL is not necessarily linked to objective physical status, symptoms and age.
The results of our study clearly show that at the end of inpatient treatment, patients assess their physical, psychological and functional status as better than at the beginning of therapy. As there are no normative values for AML patients, the numbers as such do not clarify the individual patient's assessment. The tendency of changes in the relevant QL domains of patients undergoing treatment can enlighten the development of subjective well-being during and after therapy. The practical meaning of these results can be translated as: At the end of inpatient treatment, patients' physical fitness has improved and patients are emotionally more relaxed. Patients' ability to fulfill minor tasks in and around the house has improved and the impairment of their social activities is decreasing.
Although only a minority of patients with AML remain in continuous complete remission, the evaluation of QL in patients undergoing treatment shows that subjective benefit outweighs the adverse effects of antileukemic therapy. This is unexpected since one would assume that treatment toxicity and poor prognosis would be associated with poor QL. For example, a number of studies with breast cancer patients [13] [14] [15] highlight the fact that patients set different priorities in defining their individual QL compared to what doctors and nurses would consider, eg patients may trade more toxicity for a brief extension of life. 16 As clarified by the qualitative data, patients' QL is very much influenced by aspects of the inpatient setting, especially the quality of hospital food. At a first glance this may seem to be a minor fact. But if one takes into account that patients have usually only very reduced ways of experiencing the outside world, the sensual enjoyment of food intake plays a dominant role in their subjective well-being. The interviews revealed major factors influencing patients' psychosocial wellbeing: back home patients have to cope with the instability of their daily routine and the fear of a relapse. As patients stated, recurrent offers to talk about whatever seems vital to Changes in EORTC-QLQ C30 functioning subscales during inpatient treatment (a higher score indicating better functioning).
them can help patients adjust to their situation and can even encourage them to see positive changes in their life. In the interview, 12 patients reported spontaneously about a kind of secondary benefit they experience from their disease: those patients claim they get a different perspective on life, being ill makes them readjust their priorities, life has become more valuable to them and therefore they are able to enjoy it in a very intensive way. In a Swedish study 17 AML patients who experienced a change of attitude towards life reverted to their earlier lifestyle within 2 years after therapy. Several studies of QL in patients having undergone a bone marrow transplantation -a treatment regimen comparable in many ways to prolonged intensive chemotherapy in AML -report that most long-term survivors assess their QL 5 or more years after BMT as good or excellent 18 and have resumed a normal life. 19 The results of our study underline the importance of including short-term aspects of QL as subjective indicators in assessing the impact of therapy. In focussing short-term aspects of QL
Figure 4
Changes in EORTC-QLQ C30 symptom scales during inpatient treatment (a higher score indicating a greater degree of symptoms).
medical staff and nurses can enhance patients' compliance and coping strategies.
